The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
These advanced tools allow researchers to screen millions of compounds from chemical databases to identify promising therapeutic candidates, significantly reducing the time and cost typically required to explore the vast chemical space.
In clinical trials, AI models enhance the selection of patient populations and help predict outcomes, leading to higher success rates for novel drug development.
However, as AI becomes more embedded in the drug discovery pipeline, regulatory bodies have stepped up efforts to ensure these technologies are integrated safely and ethically. To that end, regulators are increasingly engaging with industry stakeholders to adapt and evolve policy frameworks.
Beyond AI, cloud-based technologies are pivotal in modernizing regulatory submissions and data exchange. Cloud platforms enable real-time collaboration and offer greater flexibility in product development and lifecycle management.
Despite these advantages, cloud-based systems also raise concerns about data security and intellectual property protection. These risks have prompted regulators to develop more stringent guidelines aimed at safeguarding sensitive information.
To support evidence-based decisions, regulatory agencies are also leveraging real-world evidence (RWE). Multiple studies suggest that incorporating RWE into regulatory evaluations has improved the overall quality of decisions on new drug approvals.
Standardization is another key focus area. Broader adoption of the electronic common technical document (eCTD) format within the International Council for Harmonisation (ICH) framework is helping bring greater consistency to regulatory submissions.
Standardized documentation not only reduces duplication and minimizes errors but also provides pharmaceutical companies with a more predictable and streamlined submission process.
Reference:
Regulatory Trends in Pharma Manufacturing: Key Changes to Watch in 2025
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
Diacetone Alcohol (DAA) is an aliphatic hydroxy ketone produced through the base-catalysed aldol addition of two acetone molecules. It contains both ketone and tertiary hydroxyl functionalities, offering excellent solvency and chemical reactivity.
As a high-boiling oxygenated solvent and valuable chemical intermediate, DAA finds broad application in paints and coatings, printing inks, adhesives, industrial cleaning, cosmetics, and textiles. It is also used as an intermediate in the production of mesityl oxide and MIBK. (4-methylpentan-2-one).